

NOVADEL PHARMA INC

Form 8-K

June 09, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) June 9, 2010

NOVADEL PHARMA INC.  
(Exact Name of Registrant as Specified in Its Charter)

|   |                                    |   |
|---|------------------------------------|---|
| Delaware<br>(State or other jurisdiction<br>of incorporation or organization) | 001-32177<br>(Commission File No.) | 22-2407152<br>(I.R.S. Employer<br>Identification No.) |
|---|------------------------------------|---|

1200 Route 22 East, Suite 2000  
Bridgewater, New Jersey 08807  
(Address of principal executive offices) (Zip Code)

(908) 203-4640  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
-

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure

On June 10, 2010, beginning at 9:00 a.m., Eastern Standard Time, the 2010 Annual Meeting of Stockholders of NovaDel Pharma Inc., a Delaware corporation (the “Company”), will be held at the offices of Morgan, Lewis & Bockius LLP, located at 502 Carnegie Center, Princeton, New Jersey 08540. In connection with this meeting, the Company has made available for review on its website an updated copy of its Corporate Presentation at [www.novadel.com](http://www.novadel.com). A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information furnished pursuant to this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 NovaDel Pharma Inc. Corporate Presentation dated June 9, 2010.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma Inc.

By: /s/ Steven B.  
Ratoff  
Name: Steven B.  
Ratoff  
Title: Chairman,  
Interim Chief  
Financial  
Officer,  
President and  
Chief  
Executive  
Officer

Date: June 9, 2010

---

